Discover the power of real-time signals plus AI
Every contract, funding round, exec hire, and M&A move on HOPO Therapeutics — with verified, ICP-scored contact reveals (email + mobile) on demand.
Trusted by founders, sales teams, recruiters, and investors at firms like BlackRock, Oracle, Kleiner Perkins, and HubSpot.
HOPO Therapeutics Awarded $226 Million Contract from BARDA for Advanced Development of Oral Decorporation Agent
Contract Type
contract
Description
HOPO Therapeutics, Inc. has been awarded a contract valued at up to $226 million from the Biomedical Advanced Research and Development Authority (BARDA) to advance the development of the drug candidate HOPO-101 as a medical countermeasure against radiological threats. The funds will be used for toxicology and pharmacology studies, manufacturing activities, and nonclinical research in heavy metal poisoning, with additional funding available for later-stage development upon agreement between BARDA and HOPO.